Vernalis Plc said that it is entering an exclusive collaboration, option and licensing agreement with GlaxoSmithKline to research an undisclosed oncology target. The deal, including milestone payments, is valued at more than $200 million. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals